This Cost-Plus-Fixed-Fee Contract With Mapp Biopharmaceutical, Inc. (mapp or Contractor) IS for the Development of Mapp?s Therapeutic Intervention MBP091, AS an Immunotherapy for the Treatment of Marburg Virus Infection
Contract Overview
Contract Amount: $110,877,385 ($110.9M)
Contractor: Mapp Biopharmaceutical, Inc.
Awarding Agency: Department of Health and Human Services
Start Date: 2022-09-28
End Date: 2031-05-01
Official Description: THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.